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Introduction: Treatment options are limited in patients with ad-
vanced or refractory non-small cell lung cancer and lead to subop-
timal outcome and/or benefit. The epidermal growth factor tyrosine
kinase inhibitor gefitinib (IRESSA) has been approved in many
countries. Increased responsiveness to gefitinib has been demon-
strated in particular subsets of patients, for example never smokers
and patients of Asian origin. However, to date, little is known of its
use specifically in patients from India.
Methods: Retrospective ad hoc analysis of clinical data from
experience with gefitinib in patients with advanced NSCLC from
India enrolled in the IRESSA Survival Evaluation in Lung (ISEL)
study (n 77) or included in the gefitinib expanded-access program
in India (n  133).
Results: Among Indian patients enrolled in the ISEL study, median
survival was 6.4 months with gefitinib and 5.1 month with placebo.
The objective response rate in Indian patients was 14% with ge-
fitinib versus 0% with placebo. In ISEL, tolerability data from
Indian patients were consistent with the overall study population. In
the Indian gefitinib expanded-access program, median survival was
6 months and gefitinib was well tolerated.
Conclusions: Gefitinib seems well tolerated in Indian patients with
advanced NSCLC, with some clinical benefit observed.
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Until recently, lung cancer was considered rare in India,but has quickly become a significant cause of morbidity
and mortality1; it is estimated that 43,500 Indian patients are
diagnosed with lung cancer every year and 37,500 will die of
the disease.2 Furthermore, the Indian Council of Medical
Research reports that lung cancer is one of the commonest
cancers among Indian men, and is particularly prevalent in
Delhi, Mumbai, and Bhopal.3
The lung cancer treatment regimens currently in use in
India follow the internationally accepted standard schedules
and protocols that are applicable to the distinctive clinical
profile of the disease in this patient population. Interestingly,
Indian patients tend to present with the disease at an earlier
age than Western patients.4 Such differences may partly be
due to the unique smoking habits of the Indian population, for
example bidi smoking (smoking aged Indian tobacco
wrapped in a temburni leaf), which has a higher risk of lung
cancer than cigarette smoking.5 In India, first-line treatment
for advanced (stage IIIb–IV) non-small cell lung cancer
(NSCLC) is usually with platinum-based doublet chemother-
apy, and second-line treatment is commonly monotherapy
with gemcitabine or paclitaxel. These treatment options are
applicable in patients with a good performance status. In
addition, radiotherapy is the preferred option for pain control
and palliative treatment in patients in whom other organs
have been compromised due to tumor growth.1,6,7
Gefitinib (IRESSA) is an epidermal growth factor re-
ceptor tyrosine kinase inhibitor (EGFR-TKI) that has been
extensively investigated in NSCLC.8–10 Several studies have
shown increased responsiveness to gefitinib in specific patient
populations, most notably in patients of Asian origin.11–15
Response rates of 15 to 71% have been reported in patients of
Asian origin compared with 5.3 to 29% in patients of non-
Asian origin.11–15
The recent international Phase III study—IRESSA Sur-
vival Evaluation in Lung cancer (ISEL)—of gefitinib in the
treatment of advanced NSCLC showed some improvement in
survival in the overall population with gefitinib compared
with placebo, but this improvement did not reach statistical
significance (hazard ratio [HR] 0.89; 95% confidence interval
[CI]: 0.77–1.02; p  0.087).10 However, preplanned sub-
group analyses showed significantly longer survival in the
gefitinib group than the placebo group for patients of Asian
origin (HR 0.66; 95% CI: 0.48–0.91; p  0.01) [Figure 1].
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Significant improvements with gefitinib compared with pla-
cebo in time to treatment failure (time to treatment failure
[TTF], median 3.0 versus 2.6 months, respectively; HR 0.82;
95% CI: 0.73–0.92; p  0.0006) and OR rate (8% versus
1.3%, respectively; odds ratio 7.28; 95% CI: 3.13–16.91; p
0.0001) were seen in the overall population (Figures 1 and
2).10 On the basis of the significant interactions observed in
survival for racial origin, it was judged that exploratory
subgroup analyses for these secondary endpoints would be
appropriate to ascertain whether the trial was internally con-
sistent with respect to the findings on survival in subsets. The
results for TTF were similar to those for survival for patients
of Asian origin with a median TTF of 4.4 months for gefitinib
and 2.2 months for placebo (HR: 0.69, 95% CI: 0.52–0.91;
p  0.0084) (Figure 2). Objective response (OR) rates were
also higher for gefitinib than for placebo in patients of Asian
origin (Figure 3).16
Subset analyses are conducted to assess whether differ-
ent subgroups of patients respond differently to the interven-
tion under investigation.17,18 In the ISEL study, subset anal-
yses were preplanned, and a rigorous statistical approach was
used to reduce the chance of false-positive results. However,
there is a lack of published data on the use of gefitinib in
patients in India. Therefore, it is not yet known whether
Indian patients respond to gefitinib in a similar manner to
Western populations or to patients of Asian origin. Here we
review the current clinical experience with gefitinib in such
Indian patients, with data from patients in India enrolled in
the ISEL trial and those treated as part of the gefitinib
compassionate-use expanded-access program (EAP) in India.
Gefitinib in Patients from India: Phase III Data
from ISEL
ISEL (study no: 1838IL/709) was a double-blind, placebo-
controlled, parallel-group, multicenter, randomized study that
enrolled 1692 patients with locally advanced or metastatic
NSCLC from 28 countries in Europe, Asia, Central and South
America, Australia, and Canada. All patients had received
one or two prior chemotherapy regimens and were refractory
or intolerant to the most recent regimen. Patients were ran-
domized in a 2:1 ratio to receive gefitinib 250 mg/d or
placebo plus best supportive care. The primary end point was
survival in both the overall population and in patients with
adenocarcinoma histology. Secondary endpoints were TTF,
OR rate, quality of life, and tolerability. Details of the ISEL study
design, including inclusion and exclusion criteria, are described by
Thatcher et al.10
A retrospective ad hoc analysis of the 77 patients from
Indian centers who were enrolled on the ISEL study was
carried out. This was not a preplanned analysis; therefore, no
statistical analyses were performed on the data. The patients
included in the ISEL study were defined by their country of
origin rather than their ethnicity, and all Indian patients in the
ISEL trial were classified as Caucasian according to protocol
definitions. Of the 77 Indian patients, 57 (74%) were ran-
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domized to gefitinib and 20 (26%) to placebo (Table 1). The
patients’ median age was 56 years (range, 32–75) across both
treatment groups, which was lower than observed in the
overall ISEL population (median ages 62 and 61 years in the
gefitinib and placebo groups, respectively); however, this was
expected for the Indian patient population.6 In Indian pa-
tients, there was a higher proportion with adenocarcinoma
histology (60%) than in the overall ISEL population (45% in
both treatment groups). There was also a higher proportion of
never smokers in the Indian patients (52%) than in the overall
ISEL population (22% in both treatment groups); however,
the consumption of smokeless tobacco was not documented.
All other baseline demographic and disease characteristics
were similar to the overall ISEL population10 and were
generally well balanced between the two treatment groups.
In Indian patients at data cut-off, 29 (51%) patients in
the gefitinib treatment group had died compared with 12
(60%) patients in the placebo group. Median survival was 6.4
months in patients who received gefitinib and 5.1 month in
those who received placebo (Figure 1). In addition, longer
TTF was seen in the gefitinib group compared with the
placebo group (5.5 months versus 3.0 months, respectively;
Figure 2). Seven (14%) ORs (complete or partial) were seen
in the gefitinib group (95% CI: 5.9–27.2) and no ORs
occurred in the placebo group (Figure 3). Six of the 25 never
smokers had an objective response, and one of the 24 ever
smokers was a responder; however, no conclusions can be
made from this as this is a nonprotocolled subgroup of a
subpopulation analysis.
The proportion of patients who discontinued treatment
was similar between the two groups: 35 (61%) patients
withdrew from the gefitinib group compared with 13 (65%)
patients from the placebo group. There was a low incidence
of withdrawals due to adverse events (AEs): 3 (5%) patients
in the gefitinib group and 3 (15%) patients in the placebo
group. AEs were experienced by 51 (90%) patients in the
gefitinib group and 19 (95%) patients in the placebo group.
National Cancer Institute common toxicity criteria (NCI-
CTC) grade 3/4 AEs were observed in 22 (39%) patients
receiving gefitinib and 10 (50%) patients receiving placebo.
Deaths due to AEs occurred in 6 (11%) patients in the
gefitinib group (primary cause of death; NSCLC [1 patient]
and respiratory tract infection [1 patient]; silent myocardial
infarction [1 patient]; cardiopulmonary failure [1 patient];
respiratory distress [1 patient]; unknown cause [1 patient]),
and 3 (15%) patients in the placebo group (primary cause of
death; cardiopulmonary failure [1 patient]; unknown cause [2
patients]). Of the nine deaths from AEs, none were consid-
ered related to treatment.
Gefitinib in Patients from India:
Compassionate-Use Data from the EAP
One hundred and thirty-three patients with advanced
NSCLC received gefitinib 250 mg/d in the gefitinib EAP
from January 2002 to May 2004. Patients were recommended
for the EAP if they had previously documented histologically
or cytologically confirmed advanced NSCLC, and had re-
ceived at least one course of chemotherapy and/or radiother-
apy or were ineligible for chemotherapy or radiotherapy.
Baseline demographics of Indian patients in the EAP
were similar to those of Indian patients from the ISEL study:
most were male (70%), had stage IV disease (54%) and
adenocarcinoma histology (77%) (Table 2). Most patients in
TABLE 1. Baseline Demographic and Disease
Characteristics of Indian Patients in the Gefitinib Survival
Evaluation in Lung Trial (Intention-to-Treat Population)
Gefitinib
(n  57)
Placebo
(n  20)
All
(n  77)
Median age (range), yr 55 (32–75) 57.5 (39–74) 56 (32–75)
Sex, n (%)
Male 40 (70) 16 (80) 56 (73)
Female 17 (30) 4 (20) 21 (27)
Smoking history, n (%)
Never smoker 29 (51) 11 (55) 40 (52)
Smoker 28 (49) 9 (45) 37 (48)
Performance status, n (%)
0a 4 (7) 3 (15) 7 (9)
1b 33 (58) 11 (55) 44 (57)
2c 20 (35) 4 (20) 24 (31)
3d 0 (0) 2 (10) 2 (3)
Tumour histology, n (%)
Adenocarcinoma 33 (58) 13 (65) 46 (60)
Bronchoalveolar 1 (2) 0 (0) 1 (1)
Squamous cell 8 (14) 5 (25) 13 (17)
Large cell 3 (5) 1 (5) 4 (5)
Mixed (squamous cell and
adenocarcinoma)
1 (2) 0 (0) 1 (1)
Undifferentiated 11 (19) 1 (5) 12 (16)
Disease stage at diagnosis,
n (%)
I 1 (2) 1 (5) 2 (3)
II 4 (7) 2 (10) 6 (8)
IIIa 7 (12) 2 (10) 9 (12)
IIIb 15 (26) 5 (25) 20 (26)
IV 30 (53) 10 (50) 40 (52)
Time from diagnosis, n (%)
6 mo 22 (39) 7 (35) 29 (38)
6–12 mo 22 (39) 10 (50) 32 (42)
12 mo 13 (23) 3 (15) 16 (21)
Current disease status, n (%)
Locally advanced 9 (16) 3 (15) 12 (16)
Metastatic 48 (84) 17 (85) 65 (84)
Prior chemotherapy regimens,
n (%)
0 1 (2) 1 (5) 2 (3)
1 26 (46) 11 (55) 37 (48)
2 30 (53) 8 (40) 38 (49)
Reason for failure of last
chemotherapy, n (%)
Refractorye 48 (84) 18 (90) 66 (86)
Intolerant 8 (14) 1 (5) 9 (12)
Unknown 1 (2) 1 (5) 2 (3)
Best response to most recent
chemotherapy, n (%)
Partial response 7 (12) 8 (40) 15 (20)
Stable disease 9 (16) 2 (10) 11 (14)
Progressive disease 25 (44) 7 (35) 32 (42)
Non-evaluable 15 (26) 2 (10) 17 (22)
Not recorded 1 (2) 1 (5) 2 (3)
a Asymptomatic and fully active.
b Symptomatic; fully ambulatory; restricted in physically strenuous activity.
c Symptomatic; ambulatory; capable of self-care; more than 50% of waking hours
are spent in bed.
d Symptomatic; limited self-care; spends more than 50% of time in bed, but not
bedridden.
e Refractory defined as recurrent or progressive disease (clinical or radiological)
while receiving or within 90 d of last dose of chemotherapy.
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the Indian EAP had previously received treatment for
NSCLC, and only 7 (5%) patients had received no prior
chemotherapy.
The median duration of gefitinib treatment was 6
months (range, 0.5–26 months) and median survival was 6
months (range, 0.5–38 months) (Figure 4). Fifty-four (41%)
patients survived for a period of 1 to 3 months, 16 (12%)
patients survived for 4 to 6 months, 39 (29%) patients
survived for 7 to 12 months, and 24 (18%) patients survived
for over 12 months.
Although objective and subjective efficacy (including
symptomatic improvement) data were not collected prospec-
tively in all patients enrolled in the EAP, objective and
subjective responses were observed in some patients.19
Gefitinib was generally well tolerated; skin rash and
diarrhea were observed in some patients. Three patients
experienced serious AEs that led to withdrawal from the
EAP: one patient had a maculopapular rash (NCI-CTC grade
3); one patient had generalized convulsions with sudden loss
of vision20; and one patient had suspected interstitial pneu-
monia.
DISCUSSION
We have analyzed the clinical experience of gefitinib in
Indian patients from the large Phase III ISEL study and the
compassionate-use EAP. Results from the subgroup of Indian
patients in ISEL showed a median survival of 6.4 months
with gefitinib and 5.1 month with placebo. In the overall
ISEL population, the median survival in patients treated with
gefitinib compared with placebo was 5.6 versus 5.1 month in
the overall ISEL population and 9.5 versus 5.5 months in
patients of Asian origin.10,16
Analysis of the secondary end point data from the
Indian patients in the ISEL study was not preplanned; how-
ever, gefitinib seems to provide clinical benefit in terms of
TTF (5.5 months with gefitinib versus 3.0 months with
placebo) and OR rate (14% [95% CI: 5.9–27.2] with gefitinib
versus 0% with placebo). Caution must be used when inter-
preting these results as no formal statistical analyses were
performed. As the median life expectancy in India is 58.5
years for males and 59.6 years for females, the apparent lack
of survival benefit in Indian patients from the ISEL study may
be due to a greater proportion of non cancer-related deaths.
The EAP was not a clinical trial; therefore, there was no
protocol in place for formal collection of efficacy data.
Retrospective analysis of data from the Indian gefitinib EAP
shows a median survival time of 6 months, which is similar
to the median survival observed in Indian patients in ISEL.
Safety data from both the Indian subset in ISEL and the
Indian EAP indicate that gefitinib is well tolerated in this
patient population.
Differences in the baseline demography of the Indian,
Asian, and overall ISEL populations may be at least partially
responsible for the observed differences in responsiveness to
gefitinib compared with placebo. A higher proportion of
patients in the Indian and Asian subgroups in ISEL were
never smokers (52% and 41%, respectively) compared with
the overall population (22%). However, these results should
be approached with caution as consumption of smokeless
tobacco is very common in India; hence, the subgroup of
Indian never smokers may contain up to 70% of men and
49% of women who chew tobacco, but are recorded as never
smokers. Similarly, there was a higher proportion of patients
with adenocarcinoma histology in the Indian and Asian sub-
groups (60% and 61% of patients, respectively) compared
with the overall population (45%). Adenocarcinoma histol-
ogy and a history of never smoking are associated with
improved response to gefitinib.14,21–24 Furthermore, muta-
FIGURE 4. Survival in Indian patients in the gefitinib
expanded-access program.
TABLE 2. Baseline Demographic and Disease
Characteristics of Patients in the Indian Gefitinib Expanded-
Access Program
Patients
(N  133)
Median age (range), yr 53 (27–87)
Sex, n (%)
Male 93 (70)
Female 40 (30)
Smoking history, n (%)
Never smoker 31 (23)
Smokera 11 (8)
Not specified 91 (68)
Tumour histology, n (%)
Adenocarcinoma 103 (77)
Bronchoalveolar 11 (8)
Squamous cell 17 (13)
Not specified 2 (2)
Disease stage at diagnosis, n (%)
I 1 (1)
II 2 (2)
IIIa 1 (1)
IIIb 5 (4)
IV 72 (54)
Not specified 52 (39)
Prior treatments, n (%)
0 7 (5%)
1 69 (52%)
2 36 (27%)
3 4 (32%)
Not available 17 (13%)
a Includes two patients described as “ex-smokers.”
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tions in the EGFR gene confer increased sensitivity to ge-
fitinib, and these mutations have been observed at a higher
frequency in never smokers and patients with adenocarci-
noma histology.22,25–32 It has been suggested that the im-
proved clinical benefit with gefitinib observed in the Asian
subgroup could be due to these predictive demographics.16
Similarly, the apparent clinical benefit of gefitinib in Indian
patients could be due to the higher proportion of patients who
were never smokers or had adenocarcinoma histology. How-
ever, it is not yet known whether EGFR mutations also occur
in a population that uses smokeless tobacco, and to our
knowledge, no data exists on the frequency of such mutations
in Indian patients.
Tolerability data from Indian patients in the ISEL study
were consistent with the overall population, in that there was
a low incidence of withdrawals due to AEs (5% versus 11%
with gefitinib and 15% versus 5% with placebo in the Indian
and overall ISEL populations, respectively). A similar inci-
dence of AEs was observed in the gefitinib and placebo
groups in both the Indian subgroup (90% and 95%, respec-
tively) and the overall ISEL population (82% and 71%,
respectively). A similar pattern was observed with grade 3/4
AEs in the gefitinib and placebo groups in both the Indian
subgroup (39% and 50%, respectively) and the overall ISEL
population (30% and 27%, respectively). The frequency of
deaths due to AEs was slightly higher in Indian patients than
in the overall ISEL population (11% versus 5% with gefitinib
and 15% versus 4% with placebo, respectively), but the
difference between the treatment arms was small. Therefore,
the observed difference in deaths due to AEs is likely to be a
population effect rather than a treatment effect.
The results presented here from Indian patients in the
Phase III ISEL study and the Indian EAP suggest that
gefitinib is well tolerated in Indian patients with advanced
NSCLC, with some clinical benefit observed. Further pro-
spective studies are needed to confirm the efficacy of gefitinib
in Indian patients and to determine whether specific subsets
of Indian patients may derive increased benefit from gefitinib.
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